Gallagher James, McCarthy Suzanne, Byrne Stephen
Pharmaceutical Care Research Group, School of Pharmacy, Cavanagh Pharmacy Building, University College Cork, Cork, Ireland,
Int J Clin Pharm. 2014 Dec;36(6):1101-14. doi: 10.1007/s11096-014-0008-9. Epub 2014 Sep 14.
Clinical and cost-effectiveness evidence are needed to justify the existence or extension of routine clinical pharmacy services in hospital settings. Previous reviews have indicated that clinical pharmacist interventions are likely to have a positive economic impact on hospital budgets but highlighted issues relating to the quality of studies.
The primary aim of this review was to feature economic evaluations of clinical pharmacy services which targeted hospital inpatients. The review focused on the current cost-effectiveness status of different services, in addition to evaluating the quality of individual studies. Results of this systematic review were compared with cost-effectiveness and quality related findings of reviews which considered earlier time frames and alternative settings.
A systematic review of the literature included a review of the following databases: Academic Search Complete, Cochrane Library, EconLit, Embase Elsevier, NHS Economic Evaluation Database and PubMed. Only studies with an economic assessment of a clinical pharmacy service provided in a hospital setting were included. Data relating to the cost-effectiveness was extracted from eligible studies. Methodologies employed and overall quality of the studies was also reviewed. A grading system was applied to determine the quality of studies. Consolidated Health Economic Evaluation Reporting Standards statement was employed to determine which aspects of a high quality health economic study were employed.
Twenty studies were deemed eligible for inclusion. Overall, pharmacist interventions had a positive impact on hospital budgets. Only three studies (15 %) were deemed to be "good-quality" studies. No 'novel'clinical pharmacist intervention was identified during the course of this review.
Clinical pharmacy interventions continue to provide cost savings. However, the standard of studies published has stagnated or even deteriorated in comparison with those included in previous reviews. Utilisation of published guidelines at initial stages of future studies may help improve the overall quality of studies.
需要临床和成本效益证据来证明医院环境中常规临床药学服务的存在或扩展是合理的。以往的综述表明,临床药师干预可能会对医院预算产生积极的经济影响,但也突出了与研究质量相关的问题。
本综述的主要目的是对针对住院患者的临床药学服务进行经济评估。该综述除了评估个别研究的质量外,还关注不同服务当前的成本效益状况。将该系统综述的结果与考虑早期时间框架和替代环境的综述中与成本效益和质量相关的研究结果进行比较。
对文献进行系统综述,包括对以下数据库的检索:《学术搜索完整版》《考克兰图书馆》《经济学文献数据库》《Embase爱思唯尔》《英国国家卫生服务体系经济评估数据库》和《医学期刊数据库》。仅纳入对医院环境中提供的临床药学服务进行经济评估的研究。从符合条件的研究中提取与成本效益相关的数据。还对所采用的方法和研究的整体质量进行了审查。应用评分系统来确定研究的质量。采用《卫生经济评估报告标准合并声明》来确定高质量卫生经济研究采用了哪些方面。
20项研究被认为符合纳入条件。总体而言,药师干预对医院预算有积极影响。只有三项研究(15%)被认为是“高质量”研究。在本次综述过程中未发现“新颖的”临床药师干预措施。
临床药学干预继续节省成本。然而,与之前综述中纳入的研究相比,已发表研究的标准停滞不前甚至有所下降。在未来研究的初始阶段采用已发表的指南可能有助于提高研究的整体质量。